3 276

Cited 16 times in

The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment

DC FieldValueLanguage
dc.contributor.author김수경-
dc.contributor.author김혜진-
dc.contributor.author박석원-
dc.contributor.author심완섭-
dc.contributor.author안철우-
dc.contributor.author이현철-
dc.contributor.author임승길-
dc.contributor.author차봉수-
dc.contributor.author허규연-
dc.date.accessioned2014-12-21T16:35:48Z-
dc.date.available2014-12-21T16:35:48Z-
dc.date.issued2007-
dc.identifier.issn0804-4643-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/95985-
dc.description.abstractOBJECTIVE: The goal was to investigate the interrelationships between the hypoglycemic effects of rosiglitazone and the changes in the regional adiposity of type 2 diabetic patients. DESIGN AND METHODS: We added rosiglitazone (4 mg/day) to 173 diabetic patients (111 males and 62 females) already taking a stable dose of conventional antidiabetic medications except for thiazolidinediones. The abdominal fat distribution was assessed by ultrasonography at baseline and 12 weeks later. Using ultrasonographic images, the s.c. and visceral fat thickness (SFT and VFT respectively) were measured. RESULTS: Rosiglitazone treatment for 3 months improved the glycemic control. However, the response to rosiglitazone was no more than 36.4%; the deterioration of the glycemic control was found in 16.8% of subjects. In addition, rosiglitazone treatment significantly increased the body fat mass, especially the s.c. fat. However that did not alter the visceral fat content. The percentage changes in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) concentrations after treatment were inversely correlated with the increase in SFT (r=-0.327 and -0.353, P<0.001 respectively) and/or body weight (r=-0.316 and -0.327, P<0.001 respectively). Multiple regression analysis revealed that the improvement in the FPG after rosiglitazone treatment was correlated with the baseline FPG (P<0.001) and the change in the SFT (P=0.019), and the reduction in the HbA1c was related with the baseline FPG (P=0.003) and HbA1c (P<0.001) and the changes in the SFT (P=0.010) or VFT (P=0.013). CONCLUSIONS: The increase in the s.c. fat depot after rosiglitazone treatment may be an independent factor that determines the hypoglycemic efficacy.-
dc.description.statementOfResponsibilityopen-
dc.format.extent167~174-
dc.relation.isPartOfEUROPEAN JOURNAL OF ENDOCRINOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAbdominal Fat/diagnostic imaging-
dc.subject.MESHAbdominal Fat/physiology*-
dc.subject.MESHBlood Glucose/metabolism*-
dc.subject.MESHBody Composition/physiology-
dc.subject.MESHDiabetes Mellitus, Type 2/blood-
dc.subject.MESHDiabetes Mellitus, Type 2/drug therapy-
dc.subject.MESHDiabetes Mellitus, Type 2/physiopathology-
dc.subject.MESHFemale-
dc.subject.MESHGlycated Hemoglobin A/metabolism-
dc.subject.MESHHumans-
dc.subject.MESHHypoglycemic Agents/therapeutic use*-
dc.subject.MESHLipid Metabolism/drug effects-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRegression Analysis-
dc.subject.MESHRosiglitazone-
dc.subject.MESHThiazolidinediones/therapeutic use*-
dc.subject.MESHUltrasonography-
dc.titleThe increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSoo-Kyung Kim-
dc.contributor.googleauthorKyu-Yeon Hur-
dc.contributor.googleauthorBong-Soo Cha-
dc.contributor.googleauthorHyun-Chul Lee-
dc.contributor.googleauthorSung-Kil Lim-
dc.contributor.googleauthorYong-Wook Cho-
dc.contributor.googleauthorSeok-Won Park-
dc.contributor.googleauthorChul-Woo Ahn-
dc.contributor.googleauthorWan-Sub Shim-
dc.contributor.googleauthorHae-Jin Kim-
dc.identifier.doi10.1530/EJE-07-0043-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00630-
dc.contributor.localIdA01179-
dc.contributor.localIdA01496-
dc.contributor.localIdA02199-
dc.contributor.localIdA02270-
dc.contributor.localIdA03301-
dc.contributor.localIdA03375-
dc.contributor.localIdA03996-
dc.contributor.localIdA04343-
dc.relation.journalcodeJ00819-
dc.identifier.eissn1479-683X-
dc.identifier.pmid17656594-
dc.identifier.urlhttp://eje-online.org/content/157/2/167.long-
dc.contributor.alternativeNameKim, Soo Kyung-
dc.contributor.alternativeNameKim, Hae Jin-
dc.contributor.alternativeNamePark, Seok Won-
dc.contributor.alternativeNameShim, Wan Sub-
dc.contributor.alternativeNameAhn, Chul Woo-
dc.contributor.alternativeNameLee, Hyun Chul-
dc.contributor.alternativeNameLim, Sung Kil-
dc.contributor.alternativeNameCha, Bong Soo-
dc.contributor.alternativeNameHur, Kyu Yeon-
dc.contributor.affiliatedAuthorKim, Soo Kyung-
dc.contributor.affiliatedAuthorKim, Hae Jin-
dc.contributor.affiliatedAuthorPark, Seok Won-
dc.contributor.affiliatedAuthorShim, Wan Sub-
dc.contributor.affiliatedAuthorAhn, Chul Woo-
dc.contributor.affiliatedAuthorLee, Hyun Chul-
dc.contributor.affiliatedAuthorLim, Sung Kil-
dc.contributor.affiliatedAuthorCha, Bong Soo-
dc.contributor.affiliatedAuthorHur, Kyu Yeon-
dc.rights.accessRightsnot free-
dc.citation.volume157-
dc.citation.number2-
dc.citation.startPage167-
dc.citation.endPage174-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF ENDOCRINOLOGY, Vol.157(2) : 167-174, 2007-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.